On Dec. 13, 2016, Bristol-Myers Squibb announced that it would not renew its lease at the Lake Union Steam Plant site in Seattle, Washington in 2019. The company planned to transition employees from Seattle to other U.S. locations.

In Sept. 2010, Bristol-Myers Squibb completed its acquisition of ZymoGenetics in a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics for $9.75 per share. The transaction had an aggregate purchase price of $885 million.